Maintenance Of Sinus Rhythm In Non Permanent Atrial Fibrillation Therapeutics
1. Multaq patent expiration
Treatment: Reduction of the risk of hospitalization for atrial fibrillation; Management of risk of dronedarone/beta-blocker interaction in patients in sinus rhythm with a history of paroxysmal or persistent af; ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7323493 | SANOFI AVENTIS US | Solid pharmaceutical composition containing benzofuran derivatives |
Jun, 2018
(7 years ago) | |
| US5223510 | SANOFI AVENTIS US | Alkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them |
Jul, 2016
(9 years ago) | |
| US8318800 | SANOFI AVENTIS US | Solid pharmaceutical compositions containing benzofuran derivatives |
Jun, 2018
(7 years ago) | |
| US8602215 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
Jun, 2031
(5 years from now) | |
| US8410167 | SANOFI AVENTIS US | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
Apr, 2029
(3 years from now) | |
| US9107900 | SANOFI AVENTIS US | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2014 |
Drugs and Companies using DRONEDARONE HYDROCHLORIDE ingredient
NCE-1 date: 01 July, 2013
Market Authorisation Date: 01 July, 2009
Dosage: TABLET
How can I launch a generic of MULTAQ before it's drug patent expiration?
More Information on Dosage
MULTAQ family patents
